PRESENT
CTCs were detected in 88% of stage II-III breast cancer patients using a strategy in which specimen processing began within 20 min of blood draw. Our strategy of profiling small pools of ultra-pure CTCs allowed for a quantitative assessment of all detectable transcripts within a specimen. We found that the tumor biology of CTCs was very heterogeneous from patient to patient and that both known and novel biomarkers predictive of treatment response could be identified. When considering a large panel of potentially clinically actionable genes with relevance to breast cancer, few genes showed consistent upregulation. This suggests that CTCs could be used as a target discovery tool when the biomarkers specific to a given patient's tumor biology are unknown. This further suggests that relatively small panels of biomarker assays, such as quantitative real-time PCR or digital droplet PCR for circulating tumor (ct)DNA, would only be expected to be informative in the context of the presence of a candidate target.
FUTURE
CTCs and ctDNA are examples of liquid biopsies that allow for serial assessment of tumor biology in the context of tumor evolution under the selection pressure of systemic therapy. Liquid biopsies offer the advantage of profiling the diverse repertoire of tumor subclones, which may not be present in a single tumor biopsy specimen. Our study demonstrated the feasibility of using liquid biopsy studies to profile rare CTCs even in operable breast cancer patients. This technology could prove beneficial in further studies in which CTCs are used to select treatment targets or for the detection of clinically occult minimal residual disease. This general approach should be further developed with the goal of incorporation into clinical trials: first as observational candidate biomarkers with correlation to trial outcomes in targeted therapy studies. If this approach is validated in clinical trials, CTCs as liquid biopsies could be incorporated into basket trials or platform trials in which biomarkers are used to assign treatment allocation. DISCLOSURE Lang received research funds from ANGLE Parsortix. She is a speaker bureau of Genomic Health. Brownson has no conflict of interest to disclose.
